AzTrials
AzTrials

Chronic Migraine HeadacheCBT TIIPNCT07802912

Efficacy of Traditional Integrated Islamic Psychotherapy and Cognitive Behavioural Therapy for Migraine: A Randomized Controlled Trial

A study testing Cognitive Behavioral Therapy (CBT), Traditional Integrated Islamic Psychotherapy (TIIP) and Medication Group in people with Chronic Migraine Headache, run by GIFT University at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

his randomized controlled trial aims to evaluate the efficacy of Cognitive Behavioral Therapy (CBT) and Traditional Integrated Islamic Psychotherapy (TIIP) as psychological interventions for individuals with chronic migraine. Read more about this study

Who is it for?
Ages 18 to 40 years
Conditions the study is for
Chronic Migraine Headache
What is being tested?
Cognitive Behavioral Therapy (CBT), Traditional Integrated Islamic Psychotherapy (TIIP) and Medication Group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 sitePakistan
Study dates
10 Mar 2025to 20 Jul 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Aged between 18 and 40 years, the band Chen et al. (2024) identify as carrying the heaviest global burden of migraine prevalence and disability.
  • A neurologist's diagnosis of chronic migraine established in accordance with International Headache Society criteria.
  • A MIDAS total of 21 or above, so that participants carried a clinically meaningful level of impairment and had room to improve (Stewart et al., 2001).
  • A score in the mild to moderate band on at least one DASS-21 subscale, since the study concerned migraine-associated distress rather than primary psychiatric disorder (Lovibond \& Lovibond, 1995).
  • A stable prophylactic medication regimen for at least one month before enrolment, with no change planned during the study, so that any shift in outcome could not be laid at the door of a change in drugs.
  • Both men and women were eligible, so that the sample resembled the clinical population rather than one gender.
Show all 11Show fewer
  • At least primary-level education, sufficient to read and complete the self-report instruments independently.
  • Enough Urdu or English to engage with the intervention material.
  • Willingness to give written informed consent and to commit to the full schedule of six weekly sessions and both assessment appointments.
  • Residence in Gujranwala for the duration of the study and reachable by telephone, so that attendance could be monitored and attrition kept down.
  • Not receiving any other form of psychotherapy at enrolment, so that the effect of the study interventions could be isolated.

Who cannot join

  • Aged below 18 or above 40 years.
  • A diagnosed severe psychiatric disorder, including psychotic disorder, bipolar disorder, or severe major depressive disorder with active suicidality.
  • A score in the severe or extremely severe range on any DASS-21 subscale, or any indication of suicidal thinking.
  • A current need for intensive or immediate psychiatric treatment.
  • A substance use disorder within the preceding six months. Substance use and withdrawal are themselves recognised causes of headache under the International Classification of Headache Disorders (Headache Classification Committee of the International Headache Society, 2018) and independently raise scores on measures of depression, anxiety, and stress, so their inclusion would have confounded both the primary and the secondary outcomes. Six months was adopted because it maps onto the early remission specifier of the DSM-5-TR, under which someone who has met no criterion for a substance use disorder for at least three months but less than twelve is classified as in early remission (American Psychiatric Association, 2022), making it a recognised diagnostic boundary rather than an arbitrary line.
  • A neurological disorder other than migraine, such as epilepsy, brain tumour, or multiple sclerosis.
Show all 9Show fewer
  • A serious medical condition likely to interfere with participation or to confound the outcomes.
  • Concurrent psychotherapy or enrolment in another intervention study.
  • Inability to give informed consent or to comply with the study procedures.

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • GIFT University

    Gujranwala, Punjab Province, 52250

Other trials in Pakistan

About this study

his randomized controlled trial aims to evaluate the efficacy of Cognitive Behavioral Therapy (CBT) and Traditional Integrated Islamic Psychotherapy (TIIP) as psychological interventions for individuals with chronic migraine. The study will compare the effects of CBT and TIIP with a medication-only control group on migraine-related disability, headache management self-efficacy, psychological distress, and quality of life.

Read the detailed description

Chronic migraine is a disabling neurological condition that is frequently associated with psychological distress, reduced self-efficacy in headache management, and impaired quality of life. Although pharmacological treatment is commonly used to manage migraine, psychological interventions may provide additional benefits by addressing cognitive, emotional, behavioral, and coping-related factors associated with migraine.

The present study is a three-arm, parallel-group randomized controlled trial designed to evaluate and compare the efficacy of Cognitive Behavioral Therapy (CBT) and Traditional Integrated Islamic Psychotherapy (TIIP) among individuals with chronic migraine. A total of 45 participants meeting the study's eligibility criteria will be recruited and randomly allocated to one of three groups: (1) CBT, (2) TIIP, or (3) medication-only control group, with 15 participants in each group through Fish Bowl sampling,

Participants assigned to the CBT group will receive six weekly individual sessions, with each session lasting approximately 45-60 minutes. The intervention will focus on psychological and behavioral factors relevant to migraine management, including identification and modification of maladaptive thoughts, coping strategies, stress management, behavioral techniques, and headache-related self-management.

Participants assigned to the TIIP group will also receive six weekly individual sessions of approximately 45-60 minutes. TIIP will integrate Islamic psychological and spiritual principles with therapeutic techniques relevant to migraine management. The intervention will incorporate Qur'anic engagement, particularly Surah Al-Rahman, alongside concepts such as Tawheed, Fitrah, Qalb, Aql, Nafs, and Tazkiyah, with emphasis on spiritual coping, emotional regulation, cognitive reframing, gratitude, patience, and adaptive responses to illness.

Participants in the medication-only control group will continue to receive their usual pharmacological management for chronic migraine and will not receive the structured psychological interventions provided in the CBT and TIIP groups.

Outcomes will be assessed using standardized measures of migraine-related disability, headache management self-efficacy, depression, anxiety and stress, and quality of life. The primary purpose of the study is to determine whether CBT and TIIP produce improvements in these outcomes and whether TIIP demonstrates comparable or greater efficacy than CBT and medication-only treatment.

The findings of this study may contribute to the development of culturally and spiritually appropriate psychological interventions for chronic migraine and provide evidence regarding the potential role of integrated Islamic psychotherapy as an adjunctive approach to migraine management.

Being tested
Cognitive Behavioral Therapy (CBT), Traditional Integrated Islamic Psychotherapy (TIIP), Medication Group
Keywords
CBT TIIP Chronic Migraine Surah Rehman

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive Behavioral Therapy (CBT)Behavioural

    A structured six-week Cognitive Behavioral Therapy intervention consisting of weekly 45-60 minute sessions for participants with chronic migraine. The intervention targets maladaptive thoughts, emotional distress, stress management, coping strategies, behavioral responses to migraine, and self-management skills. The intervention is designed to reduce migraine-related disability and improve psychological well-being, headache self-efficacy, and quality of life.

  • Traditional Integrated Islamic Psychotherapy (TIIP)Behavioural

    A structured six-week Traditional Integrated Islamic Psychotherapy intervention consisting of weekly 45-60 minute sessions for participants with chronic migraine. The intervention integrates Islamic psychological and spiritual principles, including Tawheed, Fitrah, Qalb, Aql, Nafs, Tazkiyah, Qur'anic reflection, and coping strategies, with particular use of Surah Al-Rahman. The intervention aims to promote psychological and spiritual well-being, improve coping and headache self-efficacy, reduce psychological distress, and improve migraine-related quality of life.

  • Medication GroupOther

    Only pre and post will be taken of 15 participants to compare CBT and TIIP results

Study groups in NCT07802912
Study groupRoleWhat they receive
CBT GroupExperimentalCognitive Behavioral Therapy
Receives: Behavioral: Cognitive Behavioral Therapy (CBT); Behavioral: Traditional Integrated Islamic Psychotherapy (TIIP); Other: Medication Group
TIIPExperimentalTraditional Integrated Islamic Psychotherapy
Receives: Behavioral: Cognitive Behavioral Therapy (CBT); Behavioral: Traditional Integrated Islamic Psychotherapy (TIIP); Other: Medication Group
Medication-Only Control GroupActive comparatorMedication/Usual Care
Receives: Behavioral: Cognitive Behavioral Therapy (CBT); Behavioral: Traditional Integrated Islamic Psychotherapy (TIIP); Other: Medication Group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Migraine-Related Disability as Measured by the Migraine Disability Assessment (MIDAS)

    Change in migraine-related disability from baseline to post-intervention, assessed using the Migraine Disability Assessment (MIDAS). Lower MIDAS scores indicate less migraine-related disability. The outcome will be compared across the Traditional Integrated Islamic Psychotherapy (TIIP), Cognitive Behavioral Therapy (CBT), and medication-only groups.

    Measured: Baseline and immediately after completion of the 6-week interventio

Secondary outcomes (3)
  1. DASS 21

    Change in symptoms of depression, anxiety, and stress from baseline to post-intervention, assessed using the Depression Anxiety Stress Scale-21 (DASS-21). The three subscale scores will be examined separately to determine changes in depression, anxiety, and stress symptoms across the TIIP, CBT, and medication-only groups.

    Measured: Baseline and immediately after completion of the 6-week intervention

  2. Headache Management Self-Efficacy Scale (HMSE)

    a 25-item self-report questionnaire designed to measure an individual's confidence in their ability to prevent headache episodes and manage head pain

    Measured: Baseline and immediately after completion of the 6-week interventio

  3. WHO-QOL BREF

    a 26-question survey made by the World Health Organization. It measures a person's physical health, mind, social life, and living place to check their overall quality of life.

    Measured: Baseline and immediately after completion of the 6-week intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2026
  2. Study start10 Mar 2025
  3. Primary completion20 Jun 2026
  4. Study completion20 Jul 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07802912
Sponsor's protocol ID
24101830043@gift.edu.pk
Acronym
CBT TIIP
Status last verified
Aug 2026
First submitted
31 Aug 2026
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive Behavioral Therapy (CBT), Traditional Integrated Islamic Psychotherapy (TIIP) and Medication Group in people with Chronic Migraine Headache, run by GIFT University at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Migraine-Related Disability as Measured by the Migraine Disability Assessment (MIDAS) (time frame: Baseline and immediately after completion of the 6-week interventio). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in